-
公开(公告)号：US20150297572A1
公开(公告)日：2015-10-22
申请号：US14442392
申请日：2013-11-13
发明人： Kayvan Niazi , Shahrooz Rabizadeh , Justin Golovato , Patrick Soon-Shiong , Anne-Laure Le Ny , Oleksandr Buzko
IPC分类号： A61K31/423 , A61K31/365 , A61K9/00 , A61K31/341
CPC分类号： A61K39/39 , A61K9/0014 , A61K31/05 , A61K31/12 , A61K31/16 , A61K31/341 , A61K31/365 , A61K31/404 , A61K31/407 , A61K31/423 , A61K31/66 , A61K33/24 , A61K39/085 , A61K47/06 , A61K47/10 , A61K2039/54 , A61K2039/55511 , A61K2039/57
摘要： Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca2+ ionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.
摘要翻译： 钙通量激动剂用于增强TLR或NOD介导的刺激，从而增加宿主的免疫应答并减少愈合时间。 优选的钙通量激动剂包括Ca 2+离子载体和SERCA抑制剂，并且以协同量使用其中存在TLR或NOD受体的配体。
-
公开(公告)号：US10076529B1
公开(公告)日：2018-09-18
申请号：US15068379
申请日：2016-03-11
发明人： Kayvan Niazi , Shahrooz Rabizadeh , Anne-Laure Le Ny , Oleksandr Buzko , Justin Golovato , Patrick Soon-Shiong
IPC分类号： A61K31/635 , A61K31/426 , A61K31/454 , A61K31/444 , A61K31/496 , A61K31/4709 , A61K31/4409 , A61K31/47 , A61K31/5377 , A61K31/501 , A61K31/55 , G06F19/12 , A61K31/4545
CPC分类号： A61K31/635 , A61K31/426 , A61K31/4409 , A61K31/444 , A61K31/454 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/496 , A61K31/501 , A61K31/5377 , A61K31/55 , C07D215/52 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D498/04 , G16B5/00
摘要： Compositions, compounds, and methods with significant antiviral effect against RNA viruses and especially orthomyxoviruses are contemplated, and target the viral promoter that is formed by the 5′ and 3′-UTR sequences of the viral genome.
-
公开(公告)号：US20170128568A1
公开(公告)日：2017-05-11
申请号：US15264947
申请日：2016-09-14
发明人： Kayvan Niazi , Shahrooz Rabizadeh , Justin Golovato , Patrick Soon-Shiong , Anne-Laure Le Ny , Oleksandr Buzko
IPC分类号： A61K39/39 , A61K39/085
CPC分类号： A61K39/39 , A61K9/0014 , A61K31/05 , A61K31/12 , A61K31/16 , A61K31/341 , A61K31/365 , A61K31/404 , A61K31/407 , A61K31/423 , A61K31/66 , A61K33/24 , A61K39/085 , A61K47/06 , A61K47/10 , A61K2039/54 , A61K2039/55511 , A61K2039/57
摘要： Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca2+ ionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.
-
公开(公告)号：US09463184B2
公开(公告)日：2016-10-11
申请号：US14442392
申请日：2013-11-13
发明人： Kayvan Niazi , Shahrooz Rabizadeh , Justin Golovato , Patrick Soon-Shiong , Anne-Laure Le Ny , Oleksandr Buzko
IPC分类号： A01N43/76 , A61K31/42 , A01N43/08 , A61K31/34 , A01N43/20 , A01N43/24 , A61K31/335 , A61K31/423 , A61K31/05 , A61K31/12 , A61K31/365 , A61K31/404 , A61K31/407 , A61K33/24 , A61K9/00 , A61K47/06 , A61K47/10 , A61K31/341 , A61K31/16 , A61K31/66
CPC分类号： A61K39/39 , A61K9/0014 , A61K31/05 , A61K31/12 , A61K31/16 , A61K31/341 , A61K31/365 , A61K31/404 , A61K31/407 , A61K31/423 , A61K31/66 , A61K33/24 , A61K39/085 , A61K47/06 , A61K47/10 , A61K2039/54 , A61K2039/55511 , A61K2039/57
摘要： Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca2+ ionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.
摘要翻译： 钙通量激动剂用于增强TLR或NOD介导的刺激，从而增加宿主的免疫应答并减少愈合时间。 优选的钙通量激动剂包括Ca 2+离子载体和SERCA抑制剂，并且以协同量使用其中存在TLR或NOD受体的配体。
-
5.发明授权公开(公告)号：US09315464B1
公开(公告)日：2016-04-19
申请号：US14170353
申请日：2014-01-31
发明人： Kayvan Niazi , Shahrooz Rabizadeh , Anne-Laure Le Ny , Oleksandr Buzko , Justin Golovato , Patrick Soon-Shiong
IPC分类号： C07D215/52 , C07D401/12 , C07D401/04 , C07D405/14 , C07D413/12 , C07D413/14 , C07D401/14 , G06F19/12 , C07D498/04 , C07D417/12 , C07D417/14
CPC分类号： C07D215/52 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D498/04 , G06F19/12
摘要： Compositions, compounds, and methods with significant antiviral effect against RNA viruses and especially orthomyxoviruses are contemplated, and target the viral promoter that is formed by the 5′ and 3′-UTR sequences of the viral genome.
摘要翻译： 考虑到对RNA病毒，特别是正粘病毒具有显着抗病毒作用的组合物，化合物和方法，并靶向由病毒基因组的5'和3'-UTR序列形成的病毒启动子。
-
公开(公告)号：US10350225B1
公开(公告)日：2019-07-16
申请号：US16110634
申请日：2018-08-23
发明人： Kayvan Niazi , Shahrooz Rabizadeh , Anne-Laure Le Ny , Oleksandr Buzko , Justin Golovato , Patrick Soon-Shiong
IPC分类号： C07D417/12 , A61K31/635 , A61K31/55 , A61K31/501 , A61K31/5377 , A61K31/47 , A61K31/4409 , A61K31/4709 , A61K31/496 , A61K31/4545 , A61K31/444 , A61K31/426 , A61K31/454 , G16B5/00
摘要： Compositions, compounds, and methods with significant antiviral effect against RNA viruses and especially orthomyxoviruses are contemplated, and target the viral promoter that is formed by the 5′ and 3′-UTR sequences of the viral genome.
-
公开(公告)号：US09750805B2
公开(公告)日：2017-09-05
申请号：US15264947
申请日：2016-09-14
发明人： Kayvan Niazi , Shahrooz Rabizadeh , Justin Golovato , Patrick Soon-Shiong , Anne-Laure Le Ny , Oleksandr Buzko
IPC分类号： A01N43/76 , A61K31/42 , A01N43/08 , A61K31/34 , A01N43/20 , A01N43/24 , A61K31/335 , A61K39/39 , A61K39/085 , A61K39/00
CPC分类号： A61K39/39 , A61K9/0014 , A61K31/05 , A61K31/12 , A61K31/16 , A61K31/341 , A61K31/365 , A61K31/404 , A61K31/407 , A61K31/423 , A61K31/66 , A61K33/24 , A61K39/085 , A61K47/06 , A61K47/10 , A61K2039/54 , A61K2039/55511 , A61K2039/57
摘要： Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca2+ ionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.015 秒)
